pSivida VP of Research to Discuss Company’s Protein and Antibody Sustained Delivery System at 5th Ocular Diseases and Drug

  pSivida VP of Research to Discuss Company’s Protein and Antibody Sustained
  Delivery System at 5th Ocular Diseases and Drug Development Conference

Business Wire

WATERTOWN, Mass. -- March 20, 2013

pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a specialty pharmaceutical company that
is a leader in the development of sustained release ophthalmic drug
treatments, today announced that the Company’s Vice President of Research, Dr.
Hong Guo, will present a paper at the 5^th Ocular Diseases and Drug
Development Conference in San Francisco on March 21. Dr. Guo’s presentation
will take place at 10:30 a.m.

Dr. Guo’s presentation entitled “Sustained delivery of proteins and
anti-bodies” is expected to discuss recent developments in pSivida’s Tethadur

“One of the many challenges to the pharmaceutical industry is to develop
effective delivery systems for protein and antibody drugs,” said Dr. Paul
Ashton, President and CEO of pSivida. “Dr. Guo will describe results we have
had with our proprietary Tethadur system, which is based on bioerodible,
nanostructured, porous silicon. With the large number of biologic patents
expiring and the development of the Bio-similar field, improved protein
delivery will become increasingly important.”

pSivida has previously announced a technology evaluation agreement with a
leading global biopharmaceutical company investigating the use of this
technology in ophthalmology.

The Ocular Diseases and Drug Development Conference promotes the discovery of
ocular disease development by bringing together leading scientists,
researchers and experts to discuss and collaborate on the latest research and
development, safety assessment, regulatory issues and drugs in development for
combating and curing age-related macular degeneration (AMD), diabetic
retinopathy, glaucoma, DME, uveitis and other ocular diseases. Among those
participating are representatives from most of the pharmaceutical companies
that are involved in the development of treatments for these conditions.

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drugs delivery products designed to release drugs at a controlled and
steady rate for months or years. pSivida is currently focused on treatment of
chronic diseases of the back of the eye utilizing its core technology systems,
Durasert™ and BioSilicon™. Two FDA-approved products, Vitrasert™ and Retisert™
are licensed to Bausch & Lomb. The company has licensed ILUVIEN® for DME to
Alimera Sciences and that product has received marketing authorization in
Austria, France, Germany, Portugal, Spain and the UK. pSivida has clinical
trials ongoing for the treatment of posterior uveitis and glaucoma and ocular
hypertension. Other technologies under development by pSivida include protein
and antibody delivery systems in early clinical stages.

1995: Various statements made in this release are forward-looking, and are
inherently subject to risks, uncertainties and potentially inaccurate
assumptions. All statements that address activities, events or developments
that we intend, expect or believe may occur in the future are forward-looking
statements. The following are some of the factors that could cause actual
results to differ materially from the anticipated results or other
expectations expressed, anticipated or implied in our forward-looking
statements: uncertainties with respect to: Alimera's ability to finance,
achieve additional marketing approvals, successfully commercialize and achieve
market acceptance of, and generate revenues to pSivida from, ILUVIEN for DME
in the EU; outcome of reimbursement for ILUVIEN in the U.K., Alimera's
resubmission of its NDA for ILUVIEN for DME and its ability to obtain
regulatory approval for, and if approved, to finance, successfully
commercialize and achieve market acceptance of, and generate revenues to
pSivida from, ILUVIEN for DME in the U.S.; financing and success of Phase III
posterior uveitis trials including efficacy, side effects and risk/benefit
profile of the posterior uveitis micro-insert; initiation, financing and
success of Latanoprost Product Phase II trials and exercise by Pfizer of its
option; development of products using Tethadur and BioSilicon; initiation and
completion of clinical trials and obtaining regulatory approval of product
candidates; adverse side effects; ability to attain profitability; ability to
obtain additional capital; further impairment of intangible assets;
fluctuations in operating results; decline in royalty revenues; ability to,
and to find partners to, develop and market products; termination of license
agreements; competition and other developments affecting sales of products;
market acceptance; protection of intellectual property and avoiding
intellectual property infringement; retention of key personnel; product
liability; consolidation in the pharmaceutical and biotechnology industries;
compliance with environmental laws; manufacturing risks; risks and costs of
international business operations; credit and financial market conditions;
legislative or regulatory changes; volatility of stock price; possible
dilution; possible influence by Pfizer; absence of dividends; and other
factors described in our filings with the SEC. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Our forward-looking statements speak only as of the dates on which
they are made. We do not undertake any obligation to publicly update or revise
our forward-looking statements even if experience or future changes makes it
clear that any projected results expressed or implied in such statements will
not be realized.


In US:
Martin E. Janis & Company, Inc.
Beverly Jedynak, President
312-943-1123; 773-350-5793 (cell)
In Australia:
pSivida Corp.
Brian Leedman, Vice President, Investor Relations
+61 (0) 41 228 1780
Press spacebar to pause and continue. Press esc to stop.